|Bid||180.25 x 1300|
|Ask||181.00 x 1200|
|Day's Range||178.10 - 186.34|
|52 Week Range||76.59 - 331.68|
|Beta (5Y Monthly)||1.60|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 05, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||271.75|
Dr. Michael Gonzalez, Emergency Medicine Physician & Assistant Professor at Baylor College of Medicine, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
With Covid-19 vaccination rates slowing around the world, now is not the time to buy biotechnology company Novavax (NASDAQ:NVAX) stock. Source: Ascannio/Shutterstock.com NVAX stock fell 10% between July 20 and July 27 as hope fades that the company will be able to get its Covid-19 vaccine to market in time to capitalize on demand for immunization against the deadly respiratory disease. Novavax’s share price has now declined 23% since the end of April and is 37% below its 52-week high reached in
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.